---
title: "Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295842779.md"
description: "The drug AKTX-101 is progressing through activities preparing for Investigational New Drug (IND) approval to start a Phase 1 clinical trial around mid-2027."
datetime: "2026-08-13T20:16:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295842779.md)
  - [en](https://longbridge.com/en/news/295842779.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295842779.md)
generator: "portal-rs"
---

# Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform

The drug AKTX-101 is progressing through activities preparing for Investigational New Drug (IND) approval to start a Phase 1 clinical trial around mid-2027.

### Related Stocks

- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)

## Related News & Research

- [Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast](https://longbridge.com/en/news/297190869.md)
- [Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy](https://longbridge.com/en/news/296250397.md)
- [Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models](https://longbridge.com/en/news/296231720.md)
- [Agree Realty director John Rakolta Jr acquires ADC common shares worth $1.47 million](https://longbridge.com/en/news/297505716.md)
- [Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | AKTX Stock News](https://longbridge.com/en/news/296232130.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**